
With a mifepristone safety review due by March and Senate control shifting in January, the FDA faces an extended stretch without a permanent leader.
This weekly video program highlights the latest in pharmacy news, product news, and more.
This weekly video program highlights the latest in pharmacy news, product news, and more.
Featured article:






